Important Additional Information
Liminal BioSciences previously mailed the Information Circular to its shareholders on August 16, 2023. The Information Circular was filed with the
Canadian Securities Administrators (the CSA) on SEDAR+ at www.sedarplus.com. Additional details regarding the terms and conditions of the transaction as well as the rationale for the recommendations made by the special committee of the
board of directors and the board of directors of Liminal BioSciences are set out in the Information Circular, as supplemented as described herein.
In
addition, the Company, SALP and certain of their affiliates jointly filed with the SEC a transaction statement on Schedule 13E-3. BEFORE MAKING ANY VOTING DECISION, LIMINAL BIOSCIENCES SHAREHOLDERS ARE
URGED TO READ THE INFORMATION CIRCULAR, AS SUPPLEMENTED, THE SCHEDULE 13E-3 AND OTHER MATERIALS FILED WITH THE SEC AND THE CSA IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE, AS THEY WILL CONTAIN IMPORTANT
INFORMATION ABOUT THE TRANSACTION, THE PARTIES TO THE TRANSACTION AND RELATED MATTERS. Investors and security holders may obtain a free copy of the Information Circular, as supplemented, and other documents that the Company files with the SEC and
the CSA (when available) from the SECs website at www.sec.gov and from the CSAs website at www.sedarplus.com, respectively, and from Liminal BioSciences website at www.liminalbiosciences.com.
About Liminal BioSciences Inc.
Liminal BioSciences is a
development stage biopharmaceutical company focused on discovering and developing novel and distinctive small molecule therapeutics that modulate G protein-coupled receptors, or GPCR, pathways. Liminal BioSciences is designing proprietary novel
small molecule therapeutic candidates with the intent of developing best/first in class therapeutics for the treatment of metabolic, inflammatory and fibrotic diseases with significant unmet medical needs, using our integrated drug discovery
platform, medicinal chemistry expertise and deep understanding of the GPCR biology. Liminal BioSciences pipeline is currently made up of three programs. The candidate selected for clinical development, LMNL6511, a selective antagonist for the
GPR84 receptor, is expected to commence a Phase 1 clinical trial in the second half of 2023. Liminal BioSciences is also developing LMNL6326 as an antagonist for the OXER1 receptor, targeting treatment of eosinophil-driven disease, and GPR40
agonists, both of which are at the preclinical stage. In addition to these programs, Liminal BioSciences continues to explore other development opportunities to add to its pipeline.
Liminal BioSciences has active business operations in Canada and the United Kingdom.
About Structured Alpha LP
Thomvest Asset Management Ltd.
is the general partner of SALP. Thomvest Asset Management Ltd. and its affiliates are a group of investment companies that make investments on behalf of Peter J. Thomson and his family.